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Abstract
Background: Patients with acute coronary syndrome without ST-segment elevation (ACS-
-NSTE) are at risk for adverse cardiac events. Based on data in the Korean Acute Myocardial
Infarction Registry (KAMIR), we analyzed the prognosis according to the timing of percutane-
ous coronary intervention (PCI) in patients with NSTEMI in Korea.
Methods and results: 2,455 patients with NSTEMI in KAMIR were classified according to
the time interval from the onset of cardiac symptoms to PCI. Patients in Group I underwent
PCI within 24 hours of the onset of symptoms; in Group II between 24 and 48 hours; and in
Group III after 48 hours. Major adverse cardiac events (MACEs) are defined as cardiac death,
non-cardiac death, myocardial infarction, revascularization and coronary-artery bypass graft
surgery. The MACEs were compared between groups. Of the 2,455 patients, 743 (30.2%) were
assigned to Group I, 583 (23.7%) to Group II, and 1,129 (45.9%) to Group III. The total
incidence of MACEs was higher in Group I than Group III, and similar between Groups I and
II (Group I: 15.1%, Group II: 14.4%, Group III: 11.6%, p = 0.053). The incidence of MACEs
in the intermediate TIMI risk score group had decreased as the intervention time was delayed.
Conclusions: The prognosis according to the timing of PCI in patients with NSTEMI was
similar based on the data in KAMIR. TIMI risk score was related to a high incidence of
MACEs. (Cardiol J 2011; 18, 4: 421–429)
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Introduction
Patients with acute coronary syndrome with-
out ST-segment elevation (ACS-NSTE) are at risk
for adverse cardiac events [1]. There have been five
large randomized trials: VANQWISH, FRISC II,
TACTICS-TIMI 18, TIMI IIIB, and RITA-3. A rou-
tine early invasive strategy of early angiography
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followed by revascularization was compared to
a conservative strategy of angiography and subse-
quent revascularization only if medical therapy
failed, or if substantial residual ischemia was docu-
mented [2–6].
An early invasive strategy was shown to be
beneficial in the FRISC II, TACTICS-TIMI 18, and
RITA-3 studies, especially in high risk subgroups
of patients with an elevated cardiac troponin level.
As a result, the latest guidelines from the Ameri-
can College of Cardiology-American Heart Associa-
tion and the European Society of Cardiology recom-
mend an early invasive approach in high-risk pa-
tients with ACS-NSTE [7, 8].
According to the TIMACS investigators, an
early invasive strategy in patients with ACS-NSTE
did not differ much from a delayed invasive strate-
gy in preventing death, myocardial infarction (MI),
or stroke at six months [9]. Another trial from the
ICTUS investigators showed that a selective inva-
sive strategy in patients with ACS-NSTE and ele-
vated cardiac troponin produced similar rates of
death or MI compared to routine early invasive
strategy. And there was no benefit associated with
early invasive strategy, even after patients were
stratified into low-, medium-, and high-risk groups
according to the FRISC risk score [10]. Neumann
et al. [11] reported that the early invasive group of
patients with ACS-NSTE showed reduced MI and
death at 30 days compared to the delayed invasive
group after prolonged anti-thrombotic pretreat-
ment.
Thus, the question of when to perform percu-
taneous coronary intervention (PCI) in patients
with non-ST segment elevation myocardial infarc-
tion (NSTEMI) has not yet been definitively an-
swered. Clinical trials comparing the early invasive
versus the delayed invasive strategy in patients
with NSTEMI in Korea have been limited. Based
on the data in the Korean Acute Myocardial Infarc-
tion Registry (KAMIR), we decided to analyze the
prognosis according to the timing of PCI in patients
with NSTEMI in Korea.
Methods
Study population and study design
This study was based on 2,455 patients with
NSTEMI whose details were in the KAMIR be-
tween October 2005 and February 2008, gathered
from 40 hospitals in Korea. These hospitals were
high-volume centers with facilities for PCI and on-
site cardiac surgery. Eligible patients met all three
of the following criteria: 1) symptoms of ischemia
that were increasing or occurred at rest; 2) an ele-
vated cardiac troponin I level (≥ 0.07 ng/mL);
3) ischemic changes as documented by electrocar-
diography (ECG), or a documented history of coro-
nary artery disease (CAD).
Optimal medical treatment
The patients received 200 to 300 mg of aspirin
at the time of admission, and this was followed by
at least 100 mg aspirin daily for an indefinite period;
300 to 600 mg of clopidogrel was also immediately
given, with 75 mg clopidogrel daily thereafter. The
doses of aspirin and clopidogrel varied among the
hospitals; 200 mg of cilostazol was selectively gi-
ven daily. Angiotensin converting enzyme inhibitor,
angiotensin receptor blocker, glycoprotein IIb/IIIa
inhibitor (abciximab and tirofiban), statin, unfrac-
tionated heparin, low molecular weight heparin and
beta-blocker were administered according to the
attending doctor’s decision.
Treatment strategy
Patients with NSTEMI were classified accord-
ing to the time interval from the onset of cardiac
symptoms to PCI. Patients in Group I underwent
PCI within 24 hours of the onset of symptoms,
Group II between 24 and 48 hours, and Group III
after 48 hours. All patients with NSTEMI were
eventually treated with PCI.
Clinical outcomes
The clinical outcomes were evaluated based on
major adverse cardiac events (MACEs) during the
follow-up period. These comprise cardiac death,
non-cardiac death, MI, revascularization and coro-
nary-artery bypass graft surgery. The MACEs were
compared between groups. MI is defined as docu-
mented myocardial necrosis, such as the elevation
of myocardial enzymes or the occurrence of ECG
evidence of a new Q wave. Revascularization is de-
fined as repeated PCI during the follow-up period
including target-vessel revascularization or target-
-lesion revascularization. Coronary-artery bypass
surgery is defined as open heart surgery for any
reason.
Risk stratification using TIMI risk score
The seven TIMI risk score predictor variables
were: age 65 years or older; at least three risk fac-
tors for CAD; prior coronary stenosis of 50% or
more; ST-segment deviation on ECG at presenta-
tion; at least two anginal events in prior 24 hours;
use of aspirin in prior seven days; and elevated se-
rum cardiac markers. The patients were classified
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into three groups according to their TIMI score.
The Low group had a TIMI risk score of 2 or be-
low, the Intermediate group had a TIMI risk score
of between 3 and 4, and the High group had a score
of 5 or above. We analyzed each group in its rela-
tions between incidence of MACEs and PCI-time
interval.
The study was approved by the local bioethical
committee and all patients gave their informed consent.
Statistical analysis
Continuous variables with normal distributions
were expressed as means ± standard deviation and
compared with the use of an ANOVA. Categorical
variables were compared with the use of the c2 test.
The authors performed statistical analysis to find
out the relation between the timing of intervention
and cardiac events. Multiple variables affecting the
incidence of cardiac events were identified using
univariate Cox regression analysis. The incidence of
cardiac events between groups was calculated using
multivariate Cox regression analysis. A p value of
less than 0.05 was deemed statistically significant.
All statistical analysis was done using Statistical
Package for Social Sciences software (SPSS 17.0 for
Windows).
Results
Baseline characteristics
Of the total of 2,455 patients, 743 (30.2%) pa-
tients were assigned to Group I, 583 (23.7%) to
Group II, and 1,129 (45.9%) to Group III. Baseline
characteristics are listed in Tables 1 and 2. Age, sex,
risk factor, and angiographic characteristics were
all similar among the three groups. There were no
differences of medication among the three groups
except glycoprotein IIb/IIIa inhibitor, which was
used more in Groups I and II than in Group III
(Group I: 14.8%, Group II: 13.4%, Group III: 10.5%,
p = 0.018). Regarding the Killip class, Group III was
higher than Group I (Killip class I, II — Group I:
67.0% vs Group II: 58.6%, Killip class III, IV — 3.1%
vs 7.5% respectively). The level of pro-brain natri-
uretic peptide (BNP) was higher in Group III than
Group I (Group I: 1,790 pg/mL, Group III: 2,945 pg/
/mL, p < 0.01). Cardiac marker, peak level of tropo-
nin I and creatine kinase (CK)-MB had a higher
serum level in Group I than Group III (peak CK-
-MB: 134 mg/L vs 53.5 mg/L, troponin I: 34.7 ng/mL
vs 18.2 ng/mL respectively, p < 0.01). The overall
incidence of procedure-related complication was
higher in Group I compared to Group III (9.2% in
Group I, 7.1% in Group III, p < 0.01). Considering
Killip class, pro-BNP, and peak cardiac enzyme,
group I was probably higher than Group III. But
mean TIMI risk scores were statistically no differ-
ent among the three groups (Group I: 2.15 ± 1.15,
Group II: 2.20 ± 1.17, Group III: 2.27 ± 1.18,
p = 0.094). Mean time intervals from symptom on-
set to PCI were 11.9 ± 6.5 h in Group I, 33.6 ± 6.8 h
in Group II, and 136.8 ± 212 h in Group III (p < 0.01).
Clinical outcomes
The incidence of MACEs during the follow-up
period is shown in Table 3. Total median follow-up
period was 338 days, i.e. nearly one year. In Group I,
the median follow-up period was 328 days, similar
to the 345 days in Group III. A total of 329 patients
experienced major adverse cardiac events. The to-
tal incidence of MACEs was higher in Group I than
in Group III and similar between Groups I and II
(Group I: 113/743, 15.1%; Group II: 83/583, 14.4%;
Group III: 132/1129, 11.6%, p = 0.053). By using
uni- and multivariate analysis, we found that Group I
had a higher incidence of MACEs than Group III,
and this difference was statistically significant
(p = 0.008, multivariable adjusted hazard ratio [HR]
0.551, 95% confidence interval [CI] 0.351–0.865).
Group II had a lower incidence of MACEs than
Group I, but without statistical significance:
p = 0.18, multivariable adjusted HR 0.74, 95% CI
0.436–1.256 (Table 4). Further factors potential in-
fluencing the incidence of MACEs were the prese-
nce of procedure-related complications (HR 2.335,
95% CI 1.45–3.77), cases of multi-vessel disease
(HR 2.157, 95% CI 1.36–3.43), and the use of gly-
coprotein IIb/IIIa inhibitors (abciximab, tirofiban)
(HR 1.761, 95% CI 1.27–2.43) (Table 4). We ana-
lyzed cardiac death and MI according to PCI tim-
ing, and found the risk of cardiac death and MI was
similar among the three groups (Fig. 1)
Risk stratification by TIMI risk score
The TIMI risk scores between the three
groups are set out in Table 5 as well as mean TIMI
risk score between the groups. Patients who had
delayed invasive intervention had a higher TIMI
risk score than patients who had early invasive in-
tervention, but the difference was statistically in-
significant (Group I: 2.15 ± 1.15, Group II: 2.20 ±
± 1.17, Group III: 2.27 ± 1.18, p = 0.094). There were
no differences in the proportion of TIMI risk among
the three groups. The higher the TIMI risk score,
the higher the incidence of MACE (analysis be-
tween the groups of Low and High TIMI risk score,
HR 1.824, 95% CI 1.03–3.21). The TIMI risk scores
from each group show that the incidence of MACE
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Table 1. Baseline characteristics of patients.
Group I Group II Group III P
n = 743 (30.2%)  n = 583 (23.7%)  n = 1,129 (45.9%)
Demographic characteristics:
Age (years ± STD) 64.8 ± 13 65.5 ± 12 66.7 ± 12 0.004
Male (%) 563 (71.2) 425 (67.4) 794 (66.6) 0.09
Medical history (n, %):
Diabetes 215 (27.2) 198 (31.4) 404 (33.9) 0.03
Hypertension 389 (49.2) 335 (53.2) 654 (54.9) 0.15
History of IHD 150 (19) 118 (18.7) 236 (19.8) 0.82
Dyslipidemia 97 (12.3) 96 (15.2) 158 (13.3) 0.10
Family Hx of IHD 57 (7.3) 63 (10) 74 (6.2) 0.05
Medical conditions (n, %):
Chest pain 617 (83) 452 (77.5) 886 (78.5) 0.003
Dyspnea 149 (20.1) 139 (23.8) 304 (26.9) 0.004
Resuscitation prior to arrival 7 (0.9) 3 (0.5) 7 (0.6) 0.6
Previous angina before MI 412 (55.5) 356 (61.1) 596 (52.8) 0.005
Killip stage (n, %):
Stage III 16 (2.2) 19 (3.3) 71 (6.3) 0.012
Stage IV 7 (0.9) 2 (0.3) 14 (1.2) 0.045
Laboratory test (mean ± STD):
Glucose [mg/dL] 163 ± 75 153± 70 162 ± 85 0.026
Pro-BNP [pg/mL] 1,878 ± 4,918 2,392± 6,533 2,919 ± 6,038 0.009
Creatinine [mg/dL] 0.67 ± 0.87 0.62± 1.2 0.81 ± 1.7 0.015
CRP [mg/dL] 18.2 ± 84 13.7± 63 18.7 ± 96 0.57
Creatine kinase-MB [mg/L] 134.8 ± 391 80.1± 394 53.5 ± 80 0.00
Troponin I [ng/mL] 34.7 ± 64 20.8± 39 18.2 ± 46 0.00
Medication (n, %):
Aspirin 702 (94.5) 548 (94.0) 1,061 (93.9) 0.265
Clopidogrel 681 (91.7) 536 (92.0) 1,043 (92.4) 0.281
Cilostazol 226 (30.4) 144 (24.7) 260 (23.0) 0.00
Statin 547 (73.6) 426 (73.1) 824 (72.9) 0.112
Beta-blocker 520 (69.9) 408 (70.0) 785 (69.5) 0.702
ACEI 444 (59.8) 342 (58.7) 643 (57.0) 0.412
ARB 145 (19.5) 103 (17.7) 190 (16.8) 0.045
Glycoprotein IIb/IIIa inhibitor 110 (14.8) 79 (13.4) 118 (10.5) 0.018
IHD — ischemic heart disease; MI — myocardial infarction; BNP — brain natriuretic peptide; CRP — C-reactive protein; ACEI — angiotension converting
enzyme inhibitor; ARB — angiotension receptor blocker
Table 2. Coronary angiographic characteristics.
Group I Group II Group III P
n = 743 (30.2%)  n = 583 (23.7%)  n = 1,129 (45.9%)
Extent of coronary disease (n, %):
1-vessel disease 328 (41.5) 235 (37.2) 443 (37.2) 0.12
2-vessel disease 226 (28.6) 224 (35.5) 382 (32.1) 0.02
3-vessel disease 213 (26.9) 150 (23.8) 316 (26.5) 0.34
Left main 24 (3) 22 (3.5) 50 (4.2) 0.39
Target vessel (n, %):
LAD 319 (40.3) 246 (39) 503 (42.2) 0.39
LCx 235 (29.7) 203 (32.2) 318 (26.7) 0.41
RCA 217 (27.4) 168 (26.6) 331 (27.8) 0.87
Left main 20 (2.5) 14 (2.2) 40 (3.4) 0.31
Time interval from symptom to PCI [h] 11.9 ± 6.5 33.6 ± 6.8 136.8 ± 212 0.00
Glycoprotein IIb/IIIa inhibitor (n, %): 110 (14.8) 79 (13.4) 118 (10.5) 0.018
LAD — left anterior descending; LCx — circumflex; RCA — right coronary artery; PCI — percutaneous coronary intervention
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is related to the time interval from symptom onset
to PCI. Results acquired from the group of Low
TIMI risk score show there was increased incidence
of MACE from Group I to Group III, but without
statistical significance.
In the group of intermediate TIMI risk sco-
re, there was decreased incidence of MACE from
Group I to Group III (HR 0.446, 95% CI 0.29–
–0.69).
Table 3. Incidence of major adverse cardiac events during follow-up period.
Group I Group II  Group III P
n = 743 (30.2%)  n = 583 (23.7%)  n = 1,129 (45.9%)
Overall incidence of MACE 113 (15.1%) 83 (14.2%) 132 (11.6%) 0.053
Cardiac death 28 (3.8%) 16 (2.7%) 26 (2.3%) 0.173
Non-cardiac death 16 (2.2%) 8 (1.4%) 15 (1.3%) 0.336
Non-fatal myocardial infarction 6 (0.8%) 7 (1.2%) 13 (1.2%) 0.722
Re-PCI 59 (7.9%) 49 (8.4%) 75 (6.6%) 0.351
Coronary artery bypass grafting 4 (0.5%) 3 (0.5%) 3 (0.3%) 0.595
MACE — major adverse cardiac events; re-PCI — repeat revascularization of stenotic lesion; Non-cardiac death — death not by cardiac origin;
Cardiac death — death by cardiac origin
Table 4. Factors influencing major adverse
cardiac events by multi-variate analysis.
Variables Hazard Confidence
ratio  interval
Time interval [h]
24–47.9 0.740 0.436–1.256
≥ 48 0.551 0.351–0.865
PCI-related 2.335 1.45–3.77
complications (+)
Multi-vessel 2.157 1.36–3.43
coronary arteries
Glycoprotein IIb/IIIa 1.761 1.27–2.43
inhibitor (+)
Glucose ≥ 200 mg/dL 1.287 0.79–2.09
Creatinine ≥ 1.5 mg/dL 0.774 0.36–1.65
Diabetes 1.045 0.65–1.68
Killip stage III, IV 1.163 0.66–2.06
PCI — percutaneous coronary intervention
Table 5. TIMI risk score.
Group I Group II Group III P
n = 743 (30.2%)  n = 583 (23.7%)  n = 1,129 (45.9%)
Low risk (1–2) 495 (66.6%) 370 (63.5%) 692 (61.3%) 0.064
Intermediate risk (3–4) 225 (30.3%) 199 (34.1%) 393 (34.8%) 0.112
High risk (5–7) 23 (3.1%) 14 (2.4%) 44 (3.9%) 0.242
Mean TIMI risk score 2.15 ± 1.15 2.20 ± 1.17 2.27 ± 1.18 0.094
Figure 1. Analysis and cumulative cardiac death and
myocardial infarction rate; PCI — percutaneous coro-
nary intervention.
In the group of high TIMI risk score, as the
procedure was delayed, there was a higher inci-
dence of MACE, but with no statistical significance
(HR 1.32, 95% CI 0.35–5.02) (Fig. 2).
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Discussion
Many recent studies have shown that a selec-
tive invasive strategy after conservative treatment
obtains better results in the low ACS-NSTE risk
group, but an early invasive strategy is recommend-
ed in the high risk ACS-NSTE group [8, 12]. An
early invasive strategy was shown to be beneficial
compared to a conservative strategy in the FRISC II,
TACTICS-TIMI 18, and RITA-3 studies, espe-
cially in high risk subgroups of patients with an ele-
vated cardiac troponin level. As a result, the la-
test guidelines of the American College of Cardio-
logy-American Heart Association and the Europe-
an Society of Cardiology recommend an early inva-
sive approach in high-risk patients with ACS-NSTE
[7, 8]. An early invasive strategy is indicated in
ACS-NSTE patients who have refractory angina or
hemodynamic or electrical instability and who have
an elevated risk for clinical events.
The optimal PCI time in patients with NSTEMI
remains controversial. In the TIMACS study,
Figure 2. Analysis and cumulative events rate of TIMI risk groups; A. Low TIMI risk group; B. High TIMI risk group;
C. Intermediate TIMI risk group; D. All patients TIMI risk group; PCI — percutaneous coronary intervention.
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3,031 patients with ACS underwent either routine
early intervention (coronary angiography £ 24 h after
randomization) or delayed intervention (coronary
angiography ≥ 36 h after randomization). At six
months, death, MI, or stroke had occurred in 9.6%
of patients in the early-intervention group, com-
pared to 11.3% in the delayed intervention group.
Early intervention did not differ greatly from de-
layed intervention in preventing death, MI, or
stroke [9]. Another trial by the ICTUS investiga-
tors showed that routine early invasive strategy in
patients with ACS-NSTE and an elevated cardiac
troponin produced similar rates of death or MI over
the course of four years compared to selective in-
vasive strategy, where catheterization was done if
the patient had refractory angina or recurrent is-
chemia. And there was no benefit associated with
an early invasive strategy, even after patients were
stratified into low-, medium-, and high-risk groups
according to the FRISC risk score [10]. Neumann
et al. [11] reported that the early invasive group of
patients with ACS-NSTE showed reduced MI and
death over the course of 30 days compared to the
delayed invasive group after prolonged anti-throm-
botic pretreatment. Mean time intervals from symp-
tom onset to PCI were 2.4 hours in the early inva-
sive group, and 86 hours in the delayed invasive
group. The weak point of this study is the 30 day
short-term follow-up.
Our study did not show that an early invasive
strategy was a superior clinical outcome to a delayed
invasive strategy in patients who had an NSTEMI
who had an elevated cardiac troponin I level. The
incidence of follow-up cardiac events in Group I was
significantly higher than in other groups. The incide-
nce of cardiac events between Group II and Group III
did not show statistical significance, but there
were numerically fewer in Group III. Peak CK-MB
and troponin-I were high in our study compared to
other studies (peak CK-MB: 134 mg/L in Group I,
53.5 mg/L in Group III, troponin I: 34.7 ng/mL in
Group I vs 18.2 ng/mL in Group III). Killip class was
also higher in Group I compared to Group III. These
results meant that we performed early intervention,
because the risk of cardiovascular events had been
higher in Group I than Group III.
Other variables affected the incidence of car-
diac events,  including PCI-related complications,
multi-vessel CAD, and the use of glycoprotein IIb/
/IIIa inhibitors. There might be evidence of risk as-
sociated with early invasive intervention, and ob-
viously the complication rate was higher than the
delayed invasive intervention. But, we consider that
the risk of cardiovascular events is high in Group I.
There were relatively high TIMI scores in pa-
tients with a delayed invasive strategy. But the
TIMI risk scores between the patients did not differ
greatly, and  were not statistically significant. Al-
though meta-analyses of previous randomized trials
that compared an invasive strategy to a conservative
strategy in patients with ACS-NSTE have shown
a benefit for an invasive strategy [13, 14], the timing
of intervention in the invasive management group
of these previous studies ranged from as early as
2.4 hours after randomization in one large trial, to as
late as 96 hours in another large trial [2–6, 11, 15].
Given this wide variation in the timing of interven-
tion, there remains substantial uncertainty regard-
ing the optimal timing for intervention in patients
with NSTEMI [13]. After analyzing our figures about
the optimal timing of intervention, delayed interven-
tion may not be inferior to early intervention because
fewer cardiac events occurred. It remains difficult to
ascertain the optimal timing of intervention in pa-
tients with NSTEMI. The main benefit of an early
invasive strategy is the prevention of cardiac events
over a longer period of time. Unfortunately, this
treatment is associated with an increase in peripro-
cedural events [16]. The time–event relationship in
patients with NSTEMI in the early invasive manage-
ment could be that of a U-shaped curve: sufficient
time is needed to allow pharmacological stabilization
of plaque [11]. The early hazard seen in the early
invasive strategy in older studies appeared still val-
id and could not be adequately prevented by the use
of extensive pharmacological anti-thrombotic and
antiplatelet regimens. Conceivably, medical pre-
treatment for at least 24 hours might considerably
decrease the risk of intervention [17]. The early in-
vasive group had fewer pharmacological benefits than
the delayed invasive group. In our study, procedure-
related complications were higher in Group I than
in the other groups. And Group I showed a higher
incidence of cardiac events because of procedure-
-related complications.
In patients with NSTEMI, TIMI risk score is
a simple prognostic way of categorizing a patient’s
risk of death and ischemic events, and provides
a basis for therapeutic decision-making [18–21]. Ac-
cording to our study, the higher the TIMI score, the
higher the incidence of cardiac events. We failed to
prove this proposal, but as can be seen from the
results, there is a tendency linking delayed proce-
dure to more frequent cardiac events. The number
of patients in the group of high TIMI risk scorewas
only 82. Further clinical analysis on a larger popu-
lation might be required in order to acquire satis-
factory results.
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Limitations of the study
A limitation of our study was that even with
a large sample size of more than 2,000 patients, the
trial was simply based on registry data, not on ran-
domized control subjects. As can be seen in the
baseline characteristics, the patients in Group I had
greater cardiovascular risk compared to Group III.
The patients in Group I were confronted with
a higher risk for intervention. These circumstanc-
es may have led to higher mortality and morbidity
in Group I. There was limited data to estimate car-
diac function, which represents a further progno-
sis of patients in MI.
Conclusions
The incidence of MACE in patients with
NSTEMI presented an insignificant difference ac-
cording to the timing of PCI based on the data in
KAMIR. The clinical outcome of PCI in patients with
NSTEMI seems irrelevant to the timing of PCI. TIMI
risk score was related to a high incidence of MACE.
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